M'Liss A Hudson1, Suhong Luo2, Timothy Chrusciel2, Yan Yan3, Robert L Grubb4, Kenneth Carson5, Jeffrey F Scherrer6. 1. Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO; Clinical Research and Epidemiology Workgroup, John Cochran VAMC, St. Louis, MO. Electronic address: mlhudson@ochsner.org. 2. Clinical Research and Epidemiology Workgroup, John Cochran VAMC, St. Louis, MO. 3. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO. 4. Division of Urologic Surgery, Washington University School of Medicine, St. Louis, MO; Clinical Research and Epidemiology Workgroup, John Cochran VAMC, St. Louis, MO. 5. Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO. 6. Clinical Research and Epidemiology Workgroup, John Cochran VAMC, St. Louis, MO; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO.
Abstract
OBJECTIVE: To determine whether racial disparities exist in the use of prostate cancer screening and detection tools in veterans. METHODS AND MATERIALS: Administrative data were obtained from the Corporate Data Warehouse on a national cohort of 275,831 veterans (21% African American [AA]) between the ages of 40 and 70 years who were free of heart disease, did not have an elevated prostate specific antigen (PSA) level (>4 ng/ml), did not have other clinical signs of prostate cancer, had not been diagnosed with prostate cancer, and had not received treatment for prostate cancer between January 10, 1998 and September 30, 2000. Subjects were followed up until September 30, 2007. Regular users were defined as those with at least 1 annual visit to the Veterans Healthcare Administration (VHA) between October 1, 1998 and September 30, 2000. We sought to determine if race was significantly associated with PSA testing, the time to elevated PSA detection, the time to prostate biopsy, and the time to diagnosis of prostate cancer. Chi-square tests, logistic regression, and Cox proportional hazard models were used to test for associations between race and prostate cancer variables. RESULTS: Eighty-four percent of the veterans between the ages 40 and 70 years undergo PSA testing. AA veterans are as likely as white veterans to undergo PSA testing. Screened AA veterans are more likely to have a PSA>4 ng/ml, undergo prostate biopsy, and be diagnosed with prostate cancer than screened white veterans. The time intervals between undergoing a prostate biopsy and being diagnosed with prostate cancer were statistically significantly shorter (although unlikely of clinical significance) for AA veterans with a PSA level>4 ng/ml than that for white veterans with a PSA level>4 ng/ml. When routine care in regular VHA users was compared with that of participants in major screening trials such as Prostate, Lung, Ovarian and Colon Cancer Trial and European Study of Screening for Prostate Cancer, prostate biopsy rates were lower (30% vs. 40%-86%), prostate cancer detection rates/person biopsied were higher (49% vs. 31%-45%), and incidence of prostate cancer was 1.1% vs. 4.9% to 8.3%. CONCLUSIONS: Among regular users of the VHA for healthcare, no disparities toward AA veterans exist in the use of prostate cancer screening and detection tools. Any differences in prostate cancer treatment outcomes are not likely because of inequalities in the use of prostate cancer screening or detection tools.
OBJECTIVE: To determine whether racial disparities exist in the use of prostate cancer screening and detection tools in veterans. METHODS AND MATERIALS: Administrative data were obtained from the Corporate Data Warehouse on a national cohort of 275,831 veterans (21% African American [AA]) between the ages of 40 and 70 years who were free of heart disease, did not have an elevated prostate specific antigen (PSA) level (>4 ng/ml), did not have other clinical signs of prostate cancer, had not been diagnosed with prostate cancer, and had not received treatment for prostate cancer between January 10, 1998 and September 30, 2000. Subjects were followed up until September 30, 2007. Regular users were defined as those with at least 1 annual visit to the Veterans Healthcare Administration (VHA) between October 1, 1998 and September 30, 2000. We sought to determine if race was significantly associated with PSA testing, the time to elevated PSA detection, the time to prostate biopsy, and the time to diagnosis of prostate cancer. Chi-square tests, logistic regression, and Cox proportional hazard models were used to test for associations between race and prostate cancer variables. RESULTS: Eighty-four percent of the veterans between the ages 40 and 70 years undergo PSA testing. AA veterans are as likely as white veterans to undergo PSA testing. Screened AA veterans are more likely to have a PSA>4 ng/ml, undergo prostate biopsy, and be diagnosed with prostate cancer than screened white veterans. The time intervals between undergoing a prostate biopsy and being diagnosed with prostate cancer were statistically significantly shorter (although unlikely of clinical significance) for AA veterans with a PSA level>4 ng/ml than that for white veterans with a PSA level>4 ng/ml. When routine care in regular VHA users was compared with that of participants in major screening trials such as Prostate, Lung, Ovarian and Colon Cancer Trial and European Study of Screening for Prostate Cancer, prostate biopsy rates were lower (30% vs. 40%-86%), prostate cancer detection rates/person biopsied were higher (49% vs. 31%-45%), and incidence of prostate cancer was 1.1% vs. 4.9% to 8.3%. CONCLUSIONS: Among regular users of the VHA for healthcare, no disparities toward AA veterans exist in the use of prostate cancer screening and detection tools. Any differences in prostate cancer treatment outcomes are not likely because of inequalities in the use of prostate cancer screening or detection tools.
Authors: E David Crawford; Robert Grubb; Amanda Black; Gerald L Andriole; Ming-Hui Chen; Grant Izmirlian; Christine D Berg; Anthony V D'Amico Journal: J Clin Oncol Date: 2010-11-01 Impact factor: 44.544
Authors: Gerald L Andriole; David L Levin; E David Crawford; Edward P Gelmann; Paul F Pinsky; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Robert L Grubb; Grant Izmirlian; Lawrence R Ragard; Jonathan D Clapp; Philip C Prorok; John K Gohagan Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: E P DeAntoni; E D Crawford; J E Oesterling; C A Ross; E R Berger; D G McLeod; F Staggers; N N Stone Journal: Urology Date: 1996-08 Impact factor: 2.649
Authors: James A Talcott; Pamela Spain; Jack A Clark; William R Carpenter; Young Kyung Do; Robert J Hamilton; Joseph A Galanko; Anne Jackman; Paul A Godley Journal: Cancer Date: 2007-04-15 Impact factor: 6.860
Authors: Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok Journal: J Natl Cancer Inst Date: 2012-01-06 Impact factor: 13.506
Authors: David Schreiber; Eric B Levy; David Schwartz; Justin Rineer; Andrew Wong; Marvin Rotman; Jeffrey P Weiss Journal: Int Urol Nephrol Date: 2014-06-27 Impact factor: 2.370
Authors: Cleo A Samuel; Mary Beth Landrum; Barbara J McNeil; Samuel R Bozeman; Christina D Williams; Nancy L Keating Journal: Am J Public Health Date: 2014-09 Impact factor: 9.308
Authors: Kevin H Kensler; Claire H Pernar; Brandon A Mahal; Paul L Nguyen; Quoc-Dien Trinh; Adam S Kibel; Timothy R Rebbeck Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506